The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis

被引:446
作者
Desai, Tusar K. [1 ]
Krishnan, Kumar [2 ]
Samala, Niharika [1 ]
Singh, Jashanpreet [1 ]
Cluley, John [2 ]
Perla, Subaiah [3 ]
Howden, Colin W. [2 ]
机构
[1] William Beaumont Hosp, Dept Internal Med, Royal Oak, MI 48073 USA
[2] Northwestern Univ, Dept Internal Med, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Oakland Univ, Dept Math & Stat, Rochester, MI 48063 USA
关键词
GASTROESOPHAGEAL-REFLUX DISEASE; LAPAROSCOPIC ANTIREFLUX SURGERY; PROTON PUMP INHIBITORS; HISTOLOGIC FOLLOW-UP; HIGH-GRADE DYSPLASIA; ENDOSCOPIC SURVEILLANCE; CANCER INCIDENCE; INTESTINAL METAPLASIA; NEOPLASTIC PROGRESSION; PATHOLOGICAL RESPONSE;
D O I
10.1136/gutjnl-2011-300730
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Introduction The risk of oesophageal adenocarcinoma (OAC) in non-dysplastic Barrett's oesophagus (BO) may have been overestimated. The objective was to estimate the incidence of OAC in patients with BO without dysplasia. Methods The authors searched MEDLINE and EMBASE from 1966 to 2011 and performed a bibliographic review of previous publications, excluding abstracts, non-peer-reviewed publications and those not published in English, for prospective or retrospective studies of the incidence of OAC in patients with BO. They excluded patients with any degree of dysplasia at baseline and those without documented intestinal metaplasia. Studies were independently reviewed by two individuals. 57 of 3450 studies were included. The authors extracted information on number of patients with BO, length of follow-up, incident cases of OAC, mean age of patients, country of origin, whether prospective or retrospective, mean length of BO segments and mortality from causes other than OAC. Study quality was assessed by the Ottawa Newcastle criteria. Results The 57 included studies comprised 11 434 patients and 58 547 patient-years of follow-up. The pooled annual incidence of OAC was 0.33% (95% CI 0.28% to 0.38%). Among 16 studies that provided appropriate information on mortality, there were 56 incident cases of OAC but 684 deaths from apparently unrelated causes. Among 16 studies that provided information on patients with short-segment BO, the annual incidence of OAC was only 0.19%. Conclusions The incidence of OAC in non-dysplastic BO is around 1 per 300 patients per year. The incidence of OAC in short-segment BO is under 1 per 500 patients per year.
引用
收藏
页码:970 / 976
页数:7
相关论文
共 117 条
[1]
Barrett's esophagus: The role of laparoscopic fundoplication [J].
Abbas, AE ;
Deschamps, C ;
Cassivi, SD ;
Allen, MS ;
Nichols, FC ;
Miller, DL ;
Pairolero, PC .
ANNALS OF THORACIC SURGERY, 2004, 77 (02) :393-396
[2]
Abela JE, 2008, AM J GASTROENTEROL, V103, P2402, DOI 10.1111/j.1572-0241.2007.01746.x
[3]
ACHKAR E, 1988, AM J GASTROENTEROL, V83, P291
[4]
Surveillance in Barrett's Esophagus: An Audit of Practice [J].
Ajumobi, Adewale ;
Bahjri, Khaled ;
Jackson, Christian ;
Griffin, Ronald .
DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (06) :1615-1621
[5]
Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance [J].
Alcedo, Javier ;
Ferrandez, Angel ;
Arenas, Juan ;
Sopena, Federico ;
Ortego, Javier ;
Sainz, Ricardo ;
Lanas, Angel .
DISEASES OF THE ESOPHAGUS, 2009, 22 (03) :239-248
[6]
Barrett's surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival [J].
Aldulaimi, DM ;
Cox, M ;
Nwokolo, CU ;
Loft, DE .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2005, 17 (09) :943-950
[7]
[Anonymous], 2000, Methods for meta-analysis in medical research
[8]
BARRETT-ESOPHAGUS - EFFECT OF ANTIREFLUX SURGERY ON SYMPTOM CONTROL AND DEVELOPMENT OF COMPLICATIONS [J].
ATTWOOD, SEA ;
BARLOW, AP ;
NORRIS, TL ;
WATSON, A .
BRITISH JOURNAL OF SURGERY, 1992, 79 (10) :1050-1053
[9]
Barrett's oesophagus: results from a 13-year surveillance programme [J].
Bani-Hani, K ;
Sue-Ling, H ;
Johnston, D ;
Axon, ATR ;
Martin, IG .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2000, 12 (06) :649-654
[10]
Bartlesman J F, 1992, Eur J Cancer Prev, V1, P323, DOI 10.1097/00008469-199206000-00008